NASDAQ$ZNTL
Zentalis Pharmaceuticals Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported financial results for the first quarter of 2024 and highlighted recent corporate accomplishments.
Zentalis Pharmaceuticals reported its Q1 2024 financial results, highlighting a cash, cash equivalents, and marketable securities position of $489.0 million. The company anticipates a catalyst-rich period in the second half of 2024 and into 2025, focusing on the clinical profile of azenosertib.
- Azenosertib clinical development plan remains on track with multiple data readouts anticipated in the second half of 2024 and into 2025.
- Final results from Phase 1 study of azenosertib in combination with gemcitabine in adult and pediatric patients with relapsed or refractory osteosarcoma to be presented at the 2024 ASCO Annual Meeting.
- Preclinical data presented at AACR demonstrated synergistic anti-tumor activity of azenosertib with KRASG12C inhibitors.
- Cash runway is projected into mid-2026.
Headline financials
Revenue & EPS history
Zentalis · Revenue · Quarterly
$40.6M
Forward guidance
Zentalis anticipates multiple data readouts in gynecological and other cancer types in the second half of 2024 and into 2025. The company expects topline data from several Phase 1/2 and Phase 2 studies, including those for azenosertib in platinum resistant ovarian cancer and recurrent or persistent USC.
Tailwinds
- Presentation of final results of Phase 1 azenosertib + chemotherapy trial in R/R osteosarcoma at 2024 ASCO Annual Meeting
- Presentation of final results of Phase 1b azenosertib monotherapy trial in solid tumors
- Topline data from Phase 1/2 MAMMOTH azenosertib + PARP inhibitor trial in platinum resistant ovarian cancer
- Presentation of initial data from Phase 1 azenosertib + BEACON regimen trial in BRAF mutant metastatic colorectal cancer
- Initial data from Phase 1 azenosertib + ZN-d5 trial in R/R AML
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2024
-1.7%
Avg return
Earnings day
-2.2%
Avg return
5 days after
+2.4%
Avg return
30 days after
58%
14 / 24 earnings
Positive
+14.5%
Q1 2023
Best reaction
-43.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.9% | -1.7% | — | |
| Q4 2025 | +3.1% | -3.7% | +49.1% | |
| Q3 2025 | +6.2% | +0.8% | +9.8% | |
| Q1 2025 | -2.5% | +3.3% | +10.7% | |
| Q4 2024 | -12.6% | -15.0% | -23.5% | |
| Q3 2024 | -2.7% | -13.9% | -22.3% | |
| Q2 2024 | -8.8% | -12.5% | -10.6% | |
| Q1 2024 | +6.1% | +7.0% | -5.5% | |
| Q4 2023 | +10.0% | +8.5% | +11.9% | |
| Q3 2023 | -43.0% | -45.0% | -33.1% | |
| Q2 2023 | +5.3% | +11.2% | -0.5% | |
| Q1 2023 | +14.5% | +22.8% | +2.7% | |
| Q4 2022 | +1.2% | -2.1% | -9.1% | |
| Q3 2022 | -14.1% | -4.3% | -17.4% | |
| Q2 2022 | -0.1% | -7.3% | -8.1% | |
| Q1 2022 | -16.4% | -24.7% | +1.3% | |
| Q4 2021 | +7.6% | +5.7% | -3.2% | |
| Q3 2021 | +0.8% | -1.0% | -8.8% | |
| Q2 2021 | +4.9% | +7.1% | +39.0% | |
| Q1 2021 | -4.6% | -1.3% | -9.0% | |
| Q4 2020 | +1.4% | -0.7% | +45.7% | |
| Q3 2020 | -5.6% | -2.1% | +36.3% | |
| Q2 2020 | +1.0% | +7.2% | -10.6% | |
| Q1 2020 | +4.5% | +8.2% | +10.5% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro